The United Kingdom’s Home Affairs Committee is recommending the government widen access to unlicensed cannabis-based products for medical use via the National Health Service before the end of the current Parliament.
The National Health Service (NHS) is England’s publicly funded health care system.
ADVERTISEMENT
The government has two months to respond to the committee’s recommendation.
There are currently no licensed cannabis-based products for medical use (CBPMs) in the U.K.
And, though unlicensed CBPMs may be prescribed, none have received marketing authorization. (Epidyolex – the trade name in Europe for Epidiolex – nabilone and Sativex are considered licensed cannabis-based medicines but not CBPMs.)
“We are concerned that there is currently a lack of access on the (NHS) for patients with a genuine medical need. Access continues to be a problem,” the committee’s report noted.
Earlier this year, the U.K. disclosed that fewer than five patients received unlicensed cannabis-based
Read full article on Marijuana Business Daily
